Phase 1/2 TCR-T Library trial targeting KRAS, TP53 and EGFR mutations across six solid tumor indications is open for enrollment; continue to expect to dose...
The clinical-stage biotech saw a slight bounce-back from its lows of last week.
HOUSTON, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (“Ziopharm” or the “Company”) (Nasdaq: ZIOP), today announced the presentation of...
BOSTON (AP) _ Ziopharm Oncology Inc. (ZIOP) on Monday reported a loss of $22.7 million in its third quarter.
HOUSTON, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (“Ziopharm” or the “Company”) (Nasdaq: ZIOP), today announced financial results for...
HOUSTON, Nov. 01, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (“Ziopharm” or the “Company”) (Nasdaq: ZIOP), today announced that it will report...
• Over 50% reduction in personnel
BOSTON and HOUSTON, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (“Ziopharm” or the “Company”) (Nasdaq: ZIOP), today announced that Kevin S. Boyle, Sr., Chief Executive Officer...
Mr. Boyle brings over 20 years of executive business leadership in CEO, CFO and operational leadership roles
Accomplished key milestones in groundbreaking TCR-T Library program, including commissioning of Company’s manufacturing facility and presentation of favorable preclinical data